...
机译:糖尿病肾病研究与阿特拉森省(SONAR)试验研究的理由和议定书:糖尿病肾病的临床试验设计小说
Department of Clinical Pharmacy and PharmacologyUniversity of Groningen University Medical Center;
Pharma Development AbbVieNorth Chicago Illinois;
Department of Medicine Section of Endocrinology ASH Comprehensive Hypertension CenterUniversity;
Pharma Development AbbVieNorth Chicago Illinois;
Department of Nephrology and Mineral Metabolism National Medical Science and Nutrition Institute;
Pharma Development AbbVieNorth Chicago Illinois;
Division of NephrologyNanfang Hospital Southern Medical University National Clinical Research;
Department of Internal MedicineWake Forest School of MedicineWinston‐Salem North Carolina;
Division of NephrologyUniversity of Utah Health Sciences CenterSalt Lake City Utah;
Department of Nephrology Rheumatology Endocrinology and MetabolismOkayama UniversityOkayama‐Shi;
BHF Cardiovascular Research CentreUniversity of GlasgowGlasgow UK;
Faculty of MedicineGeorge Institute for Global Health UNSW SydneyNewtown Australia;
Department of Medicine Division of NephrologySunnybrook Health Sciences Centre University of;
Pharma Development AbbVieNorth Chicago Illinois;
Department of Medical Endocrinology RigshospitaletUniversity of CopenhagenCopenhagen Denmark;
Department of Clinical Pharmacy and PharmacologyUniversity of Groningen University Medical Center;
atrasentan; diabetic kidney disease; endothelin receptor antagonist; personalized medicine; randomized controlled clinical trial;
机译:糖尿病肾病研究与阿特拉森省(SONAR)试验研究的理由和议定书:糖尿病肾病的临床试验设计小说
机译:蛋白质组学预测和肾素血管紧张素醛固酮系统抑制TYpe 2糖尿病性白蛋白尿(PRIORITY)患者早期糖尿病肾病的预防:一项随机临床多中心试验的基本研究设计和理论基础
机译:从初发性肾病到明显的肾病的替米沙坦肾保护性研究–初发性至明显性肾病的原理,研究设计,治疗计划和基线特征:血管紧张素II受体阻滞剂,替米沙坦,2型糖尿病肾病研究(创新)
机译:糖尿病肾病:1型和2型糖尿病患者的肾脏结构研究
机译:II型糖尿病肾病(T2DN)大鼠的糖尿病肾病的遗传和生理学表征
机译:AtRasentan(SONAR)试验研究糖尿病性肾病的原理和方案:糖尿病性肾病的新型临床试验设计
机译:蛋白质组学预测和肾素血管紧张素醛固酮系统抑制TYpe 2糖尿病性白蛋白尿的糖尿病早期肾病的预防(优先):一项随机临床多中心试验的基本研究设计和理论基础